Future heart problems could be predicted by smart watches.

Published Date: 05 Apr 2023

According to a new study led by UCL researchers, wearable technology like smart watches could be used to identify people who are more likely to experience heart failure and irregular heartbeats later in life.

Read Full News

Latest News

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD Martina Porter, MD

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD Druhan Howell, MD

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

News All Time

New pill cuts 'bad' cholesterol by 60%, potentially replacing injections

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections.

New gene discoveries improve diagnosis of inherited heart disease

Centenary Institute researchers have uncovered new genetic causes of inherited heart conditions, providing families with vital answers to guide treatment and prevention.

From contraception to menopause: Why women face a higher risk of stroke

Stroke is one of the leading causes of disability worldwide. It places a huge burden on families, health systems and societies. Increasingly, strokes are not just occurring in older adults. They are affecting younger people ...

Protein found to be key in blood vessel healing after surgical injury

Surgeons in the United States perform nearly 600,000 coronary artery stent procedures and bypass surgeries every year.

New pediatric basic life support guidelines seek to improve outcomes, optimize care, says co-author

While sudden cardiac arrest in a child or adolescent is rare—about 20,000 cases occur each year in the U.S.—the survival rate when it happens outside of a hospital is estimated to be under 20%. Significantly improving ...

Extending anti-clotting treatment linked to lower rates of new clots

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds a US study published ...

High blood pressure in children nearly doubled from 2000–2020, global study finds

The rate of children and adolescents experiencing high blood pressure worldwide nearly doubled between 2000 and 2020, according to a new meta-analysis published in The Lancet Child & Adolescent Health journal.

Q&A: How to have a heart-healthy Thanksgiving

Thanksgiving is a time to gather with loved ones, give thanks, and savor the flavors of the season. But for anyone striving to eat heart-healthy, the holiday can present some challenges. With buttery sides, decadent desserts, ...

'Humanized' model developed to study heart valve stiffness

The first ever "humanized" model for aortic valve calcification paves the way for testing potential treatments.

Very low LDL-cholesterol correlates to fewer heart problems after stroke

Brigham and Women's Hospital's TIMI Study Group reports that in patients with prior ischemic stroke, very low achieved LDL-cholesterol correlated with fewer major adverse cardiovascular events and fewer recurrent strokes, ...

Plant-based diet can prevent, reverse form of heart disease in animals with hypertension

Eating a plant-based diet consisting of fruits, vegetables, nuts and legumes can help prevent and reverse heart disease in rats that have high blood pressure, according to a study published by researchers in the Institute ...

Genetic testing trifecta predicts risk of sudden cardiac death and arrhythmia

In a new Northwestern Medicine study, scientists have developed a more precise genetic risk score to determine whether a person is likely to develop arrhythmia, an irregular heartbeat that can lead to serious conditions such ...

Effectiveness of anti-clotting meds after stent placement varied in people with diabetes

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit ...

LDL cholesterol improved among veterans in program with health coaches, other resources

A quality improvement program helped reduce "bad cholesterol" (LDL or low-density lipoprotein) levels among military veterans who have heart and blood vessel disease, according to a preliminary late-breaking science presentation ...

Researchers use AI and genetics to identify early signs of a rare, life-threatening heart condition

At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of a genetic heart condition that often strikes without warning. Their work shows that early detection, ...

Sons of mothers with type 1 diabetes show early signs of vascular dysfunction

A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape ...

Recommended News For You

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.

Some triple negative breast cancers might be avoided by longer breastfeeding

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

TikTok creators perform 'roles' when sharing their hereditary cancer stories, shaping the health information they share

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia

Train Eyes so Myopia Doesn't Get Worse? Nurse Intervention for BP Post-Stroke

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Recommended Articles For You

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment 

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier 

Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development 

Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

2.

Year in Review: Chronic Lymphocytic Leukemia

3.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.

4.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

5.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

1.

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options

2.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

3.

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians

4.

Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025

5.

Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

2.

Navigating the Complexities of Ph Negative ALL - Part VII

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

5.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot